Hem › Rabdomyosarkom
Kliniska studier för Rabdomyosarkom som rekryterar i USA
26 studier för Rabdomyosarkom rekryterar deltagare vid platser över hela USA.
Städer med flest studier
- Houston, TX6 studier
- Memphis, TN6 studier
- Washington, DC5 studier
- Boston, MA4 studier
- Salt Lake City, UT4 studier
- Philadelphia, PA4 studier
- Seattle, WA3 studier
- Aurora, CO3 studier
- Dallas, TX3 studier
- Birmingham, AL3 studier
- The Bronx, NY3 studier
- Baltimore, MD3 studier
Efter delstat
- Alabama3 studier
- Colorado3 studier
- District of Columbia4 studier
- Florida3 studier
- Kalifornien7 studier
- Maryland4 studier
- Massachusetts4 studier
- New York4 studier
- Ohio5 studier
- Pennsylvania5 studier
- Tennessee8 studier
- Texas9 studier
- Utah4 studier
- Washington3 studier
Nyligen uppdaterade studier
Officiell studietext (engelska)
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
RekryterarFas 1
Ålder 3 till 39 · Alla kön · Uppdaterad 29 sep. 2026 · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RekryterarFas 1
24 Months – 18 Years · Alla kön · Uppdaterad 25 sep. 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RekryterarFas 1/2
Upp till ålder 30 · Alla kön · Uppdaterad 3 sep. 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
RekryterarFas 3
Upp till ålder 50 · Alla kön · Uppdaterad 25 aug. 2026 · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Rekryterar
Alla åldrar · Alla kön · Uppdaterad 21 aug. 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RekryterarFas 1
Ålder 1 till 23 · Alla kön · Uppdaterad 13 aug. 2026 · NCT07172958Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 6 aug. 2026 · NCT05210374Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RekryterarFas 1
Ålder 1 till 21 · Alla kön · Uppdaterad 6 aug. 2026 · NCT04715191Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
RekryterarTidig fas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 31 juli 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RekryterarFas 1/2
Ålder 1 till 30 · Alla kön · Uppdaterad 22 juli 2026 · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Rekryterar
Upp till ålder 39 · Alla kön · Uppdaterad 13 juli 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RekryterarFas 1/2
6 Months – 25 Years · Alla kön · Uppdaterad 30 juni 2026 · NCT06625190Familial Investigations of Childhood Cancer Predisposition
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 17 juni 2026 · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
RekryterarFas 2
Upp till ålder 22 · Alla kön · Uppdaterad 15 juni 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
RekryterarFas 1/2
6 Months – 30 Years · Alla kön · Uppdaterad 2 juni 2026 · NCT04796012B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RekryterarFas 1
Upp till ålder 21 · Alla kön · Uppdaterad 19 maj 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RekryterarFas 1/2
12 Months – 30 Years · Alla kön · Uppdaterad 19 maj 2026 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
RekryterarFas 1
Ålder 1 till 30 · Alla kön · Uppdaterad 15 apr. 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
RekryterarFas 2
Ålder 1 till 50 · Alla kön · Uppdaterad 13 mars 2026 · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RekryterarFas 1/2
Ålder 12 till 49 · Alla kön · Uppdaterad 19 feb. 2026 · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RekryterarFas 1
Ålder 1 till 26 · Alla kön · Uppdaterad 17 feb. 2026 · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RekryterarFas 1
Ålder 1 till 25 · Alla kön · Uppdaterad 22 jan. 2026 · NCT04995003Molecular Analysis Of Solid Tumors
RekryterarObservationsstudie
Upp till ålder 25 · Alla kön · Uppdaterad 12 nov. 2025 · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RekryterarFas 1
Upp till ålder 21 · Alla kön · Uppdaterad 3 nov. 2025 · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RekryterarFas 1
7 Months – 21 Years · Alla kön · Uppdaterad 16 okt. 2025 · NCT02508038Från ClinicalTrials.gov, data hämtad 3 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.